drugset / Trial / NCT00075777

Valproic Acid in Treating Patients With Kaposi's Sarcoma

NCT00075777

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Valproic acid may help stop the growth of Kaposi's sarcoma cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This clinical trial is studying valproic acid in treating patients with HIV-related Kaposi's sarcoma.

Timeline

Start
2005-02
Primary completion
2007-07
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Valproic Acid Small molecule 250 mg Oral

Indications